| In response to difficulties prescribing anti-tumour drugs after their inclusion in health insurance, and to issues arising from DRG [Diagnosis-Related Group] and disease-based payment policies that lead severely ill patients to undergo staged surgeries or be discharged and readmitted, will raise these concerns with regulators in coordination with the media. | 癌症
> 癌症：大多數類型 | 監管合作夥伴關係
> 與監管機構合作 | 100,000 | National | Sometimes | 114998326269 |
| We submit surveys/proposals to CFDA [China Food and Drug Administration] and CDE [Center for Drug Evaluation]. | 呼吸系統
> 肺動脈高壓 | 監管合作夥伴關係
> 與監管機構合作 | 10,000 | National | Regularly | 115007302730 |
| With respect to newly marketed medicinal products, in our capacity as the initiating body of a patient assistance programme, we gather patient perspectives and, where a therapy demonstrably meets patients' clinical needs and no clinically equivalent alternative is available in China, we advocate for its market authorisation in the country — as we have done for medicines such as secukinumab [biologic medication used to treat autoimmune conditions like plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis] and Nefecon [corticosteroid budesonide used to treat primary Immunoglobulin A nephropathy]. | 一般健康
> 公共衛生 | 監管合作夥伴關係
> 為市場授權申請作出貢獻 | 100,000 | National | Sometimes | 115023378250 |
| I have received an invitation from the CDE [药品审评中心 – Center for Drug Evaluation] to participate in a closed-door meeting. | 癌症
> 癌症：血液 | 監管合作夥伴關係
> 出席/主持與政策制定者/監管機構的會議 | 100,000 | National | Rarely | 115007439380 |
| Roundtable discussions are primarily convened by invitation from the NMPA [National Medical Products Administration]. | 癌症
> 癌症：血液 | 監管合作夥伴關係
> 出席/主持與政策制定者/監管機構的會議 | 100,000 | National | Rarely | 115008256034 |
| Communicating and raising concerns with the NHSA [国家医疗保障局 – National Healthcare Security Administration/China]. | 罕見
> 法布里病 | 監管合作夥伴關係
> 出席/主持與政策制定者/監管機構的會議 | 1,000 | National | Regularly | 115013642356 |
| We use questionnaires to gather insights into the patient population and share the resulting survey data at meetings with policymakers. | 癌症
> 癌症：大多數類型 | 監管合作夥伴關係
> 出席/主持與政策制定者/監管機構的會議 | 100,000 | National | Sometimes | 115033327817 |
| Participating in policy consultations and attending regulatory authority-led seminars that incorporate patient perspectives. | 罕見
> 罕見疾病：大多數類型 | 監管合作夥伴關係
> 出席/主持與政策制定者/監管機構的會議 | 5,000 | National | Rarely | 115063429838 |
| Submitting advocacy letters to regulatory authorities. | 罕見
> 罕見疾病：大多數類型 | 影響政策及立法
> 影響醫療保健政策及立法 | 1,000 | National | Regularly | 115029711188 |
| Policy advocacy and healthcare access support constitute the core areas of business. | 肝臟
> 肝炎 | 影響政策及立法
> 影響醫療保健政策及立法 | 100,000 | National | Regularly | 115050575369 |
| Proposals submitted to the Lianghui [两会 – the annual plenary sessions of China's National People's Congress and the Chinese People's Political Consultative Conference]. | 一般健康
> 公共衛生 | 影響政策及立法
> 參與公眾聆訊及諮詢 | 100,000 | National | Regularly | 115023383007 |
| Participating in policy consultations and attending regulatory authority-led seminars that incorporate patient perspectives. | 罕見
> 罕見疾病：大多數類型 | 影響政策及立法
> 參與公眾聆訊及諮詢 | 5,000 | National | Rarely | 115063429838 |
| We conduct research — covering areas such as pricing and related matters — and relay the findings to the relevant regulatory authorities. | 癌症
> 癌症：大多數類型 | 定價及可負擔性倡議
> 倡導公平藥品定價 | 100,000 | National | Sometimes | 115030437530 |
| Patient-facing media advocacy content relating to healthcare insurance coverage. | 癌症
> 癌症：大多數類型 | 定價及可負擔性倡議
> 倡導公平藥品定價 | 100,000 | National | Sometimes | 115032740364 |
| We raise our voice on the issue of drug pricing. | 內分泌
> 糖尿病：2型 | 定價及可負擔性倡議
> 倡導公平藥品定價 | 10,000 | Regional | Rarely | 115051912364 |
| In our capacity as the initiating organization of a Patient Assistance Program (PAP) for newly approved medicines, we gather and represent patient perspectives. Where a genuine unmet clinical need exists and no clinically viable alternative is available in China, we advocate for the regulatory approval and market authorization of therapies such as secukinumab [biologic medication used to treat autoimmune conditions like plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis] and Nefecon [corticosteroid budesonide used to treat primary Immunoglobulin A nephropathy], while providing evidence on the financial burden borne by patients. | 一般健康
> 公共衛生 | 定價及可負擔性倡議
> 解決低收入及弱勢群體的費用負擔問題 | 100,000 | National | Sometimes | 115023378250 |
| In response to difficulties prescribing anti-tumour drugs after their inclusion in the NRDL [ 国家医保药品目录 - China's National Reimbursement Drug List], and to issues arising from DRG [Diagnosis-Related Group] and disease-based payment policies that lead severely ill patients to undergo staged surgeries or be discharged and readmitted, we will raise these concerns with regulators in coordination with the media. | 癌症
> 癌症：大多數類型 | 定價及可負擔性倡議
> 追蹤及監測藥品定價／藥品短缺情況 | 100,000 | National | Sometimes | 114998326269 |
| We conduct research — covering areas such as pricing and related matters — and relay the findings to the relevant regulatory authorities. | 癌症
> 癌症：大多數類型 | 定價及可負擔性倡議
> 追蹤及監測藥品定價／藥品短缺情況 | 100,000 | National | Sometimes | 115030437530 |
| We advocate for the inclusion of medications within the national medical insurance formulary, as well as for greater ease of access to treatments. | 神經系統
> 多發性硬化症 | 定價及可負擔性倡議
> 倡導將產品納入報銷清單／國家藥品目錄 | 10,000 | National | Sometimes | 115000464773 |
| We advocate for the inclusion of medications within the national medical insurance formulary, as well as for greater ease of access to treatments. | 神經系統
> 多發性硬化症 | 定價及可負擔性倡議
> 倡導將產品納入報銷清單／國家藥品目錄 | 10,000 | National | Sometimes | 115000464773 |
| I will advocate on issues relating to pharmaceutical pricing and the inclusion of pharmaceutical products and medical devices in the national medical insurance (NMI) reimbursement market. | 內分泌
> 糖尿病：2型 | 定價及可負擔性倡議
> 倡導將產品納入報銷清單／國家藥品目錄 | 10,000 | Regional | Rarely | 115051912364 |
| Patient-facing media advocacy content relating to healthcare insurance coverage [in China]. | 癌症
> 癌症：大多數類型 | 改善存取途徑
> 促進公平獲取藥物／醫療保健 | 100,000 | National | Sometimes | 115032740364 |
| For example, patient narratives can be disseminated through media channels to communicate patient needs around medicine accessibility. | 癌症
> 癌症：大多數類型 | 改善存取途徑
> 促進公平獲取藥物／醫療保健 | 100,000 | National | Rarely | 115037193619 |
| For example, once a medicine is included in centralised procurement, it becomes unavailable for purchase outside of hospital settings. | 風濕性
> 狼瘡 | 改善存取途徑
> 促進公平獲取藥物／醫療保健 | 100,000 | National | Sometimes | 115046738886 |
| Policy advocacy and healthcare access support constitute the core areas of business. | 肝臟
> 肝炎 | 改善存取途徑
> 促進公平獲取藥物／醫療保健 | 100,000 | National | Regularly | 115050575369 |
| For example, once a medicine is included in centralised procurement, it becomes unavailable for purchase outside of hospital settings. | 風濕性
> 狼瘡 | 改善存取途徑
> 解決在獲取和管理方面的差距 | 100,000 | National | Sometimes | 115046738886 |
| Patient needs and concerns should be communicated to policy-making bodies such as the National Healthcare Security Administration [国家医疗保障局 – China's national authority responsible for healthcare security and reimbursement policy]. | 皮膚
> 皮膚狀況：大多數類型 | 以實證為基礎的患者意見
> 利用患者洞察來輔助決策 | 100,000 | National | Sometimes | 115007238824 |
| With respect to newly marketed medicinal products, in our capacity as the initiating body of a patient assistance programme, we gather patient perspectives and, where a therapy demonstrably meets patients' clinical needs and no clinically equivalent alternative is available in China, we advocate for its market authorisation in the country — as we have done for medicines such as secukinumab [biologic medication used to treat autoimmune conditions like plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis] and Nefecon [corticosteroid budesonide used to treat primary Immunoglobulin A nephropathy]. | 一般健康
> 公共衛生 | 以實證為基礎的患者意見
> 利用患者洞察來輔助決策 | 100,000 | National | Sometimes | 115023378250 |
| We use questionnaires to gather insights into the patient population and share the resulting survey data at meetings with policymakers. | 癌症
> 癌症：大多數類型 | 以實證為基礎的患者意見
> 利用患者洞察來輔助決策 | 100,000 | National | Sometimes | 115033327817 |
| For example, patient narratives can be disseminated through media channels to communicate patient needs around medicine accessibility. | 癌症
> 癌症：大多數類型 | 以實證為基礎的患者意見
> 善用患者故事及親身經歷敘述 | 100,000 | National | Rarely | 115037193619 |
| We conduct research — covering areas such as pricing and related matters — and relay the findings to the relevant regulatory authorities. | 癌症
> 癌症：大多數類型 | 以實證為基礎的患者意見
> 進行調查/研究以產生數據 | 100,000 | National | Sometimes | 115030437530 |
| We use questionnaires to gather insights into the patient population and share the resulting survey data at meetings with policymakers. | 癌症
> 癌症：大多數類型 | 以實證為基礎的患者意見
> 進行調查/研究以產生數據 | 100,000 | National | Sometimes | 115033327817 |
互動
行動與倡議
8 提及
